The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMW 2021 | Combining expert opinion and trial data to predict survival for myeloma patients receiving ide-cel
Parameswaran Hari, MD, MRCP, MS, of the Froedtert Hospital Cancer Center, Milwaukee, WI, gives an overview of his poster presentation at the IMW 2021 meeting on the findings of a prospective qualitative study which combined expert opinions with data from the KarMMa trial (NCT03361748), the retrospective KarMMa-RW study and the MAMMOTH study to estimate survival rates at three, five and 10 years for patients with multiple myeloma receiving idecabtagene vicleucel (ide-cel). The KarMMa trial, a Phase II trial investigated the use of ide-cel, a B-cell maturation antigen (BCMA) directed chimeric antigen receptor T-cell (CAR-T) therapy, for the treatment of patients with relapsed/refractory multiple myeloma. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
